Logo

Terumo BCT and Marker Therapeutics Receive the US FDA's Emergency Use Authorization for their Purification Device to Treat COVID-19

Share this

Terumo BCT and Marker Therapeutics Receive the US FDA's Emergency Use Authorization for their Purification Device to Treat COVID-19

Shots:

  • The US FDA has granted EUA to Terumo BCT's Spectra Optia Apheresis System combined with Marker Therapeutics' D2000 Adsorption Cartridge to treat patients aged ≥18yrs. with confirmed COVID-19 and are admitted to the ICU with confirmed or imminent respiratory failure to reduce pro-inflammatory cytokine levels
  • The device works by reducing the number of cytokines and other inflammatory mediators in the blood- filter it and return the filtered blood to the patient
  • The two companies collaborate to combine their existing technologies for providing a unique solution for the treatment of acute respiratory failure in COVID-19

Click here to­ read full press release/ article | Ref: Terumo BCT | Image: Terumo BCT


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions